Endocrine (Hormone) Therapy in Cancer: Receptor Biology and Clinical Evidence

1. Introduction: Exploiting Hormone Dependence

Some of the most common cancers depend on hormones for growth. Breast cancers frequently express the estrogen receptor (ER) and/or progesterone receptor (PR); prostate cancers depend on androgens. Endocrine (hormone) therapy exploits this dependency by removing the hormonal stimulus or blocking its receptor. It is among the oldest forms of systemic cancer therapy — the bilateral oophorectomy for breast cancer described by Beatson in the 1890s anticipated the modern field — and remains a backbone of treatment for hormone-receptor-positive breast cancer and prostate cancer. This article reviews the biology, drug classes, randomized evidence, resistance, and toxicity of endocrine therapy.

2. Biological Basis

In hormone-receptor-positive breast cancer, estrogen binds the ER, which dimerizes, enters the nucleus, and drives transcription of genes that promote proliferation. In prostate cancer, androgens bind the androgen receptor (AR), which functions similarly. The therapeutic strategies follow directly from this biology: reduce ligand availability (ovarian suppression, aromatase inhibition, GnRH analogues, adrenal androgen blockade), block the receptor (SERMs, SERDs, antiandrogens), or both. Because these tumors may also be driven by other pathways, endocrine therapy is often combined with targeted agents.

3. Classes of Endocrine Agents

4. Confirmed Clinical Evidence

4.1. Breast Cancer: Tamoxifen and Aromatase Inhibitors

Adjuvant tamoxifen for about five years reduces recurrence and improves survival in ER-positive early breast cancer, with benefits persisting for years after treatment ends — a finding established through the patient-level meta-analyses of the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). In postmenopausal women, third-generation aromatase inhibitors (alone or sequentially after tamoxifen) further reduce recurrence compared with tamoxifen alone. For metastatic ER-positive disease, endocrine therapy combined with CDK4/6 inhibitors is now a standard first-line approach, and newer oral SERDs are extending the range of options.

4.2. Prostate Cancer: Androgen Deprivation and Its Intensification

Androgen deprivation therapy (ADT) has been standard for decades. Randomized trials have since shown that intensifying ADT with androgen-receptor–targeted agents or with abiraterone improves overall survival in metastatic castration-sensitive prostate cancer, and that adding these agents in earlier, non-metastatic or locally advanced settings improves outcomes. This represents one of the clearest advances in prostate cancer care in the past decade.

4.3. Other Hormone-Related Cancers

Endocrine therapy is also used in endometrial cancer (progestins, in selected cases), some ovarian tumors, and in thyroid and neuroendocrine contexts through related mechanisms. The strength of evidence is greatest in breast and prostate cancer.

5. Resistance

Endocrine resistance is common and mechanistically heterogeneous. In breast cancer, acquired ESR1 mutations that confer ligand-independent ER activity are well documented and have motivated newer receptor-degrading agents. Upregulation of growth-factor signaling (for example, PI3K/AKT/mTOR pathways) and cell-cycle bypass are other mechanisms, addressed in part by CDK4/6 and PI3K inhibitors. In prostate cancer, AR amplification, mutations, and splice variants (such as AR-V7) contribute to resistance to androgen-receptor–directed therapy.

6. Toxicity

Because endocrine therapy alters normal hormonal signaling, its side effects reflect that disruption. Tamoxifen is associated with vasomotor symptoms, menstrual irregularity, and a small but real increase in venous thromboembolism and endometrial changes; aromatase inhibitors cause arthralgias, bone loss, and fracture risk (requiring monitoring). ADT causes sexual dysfunction, loss of libido, hot flushes, sarcopenia, increased fat mass, and reduced bone density, along with metabolic and cardiovascular considerations. These effects are generally non-life-threatening but are a frequent reason for reduced adherence and require active management.

7. Early Research and Emerging Approaches

• Newer oral SERDs and PROTAC degraders target ER in resistant disease and are in trials or early approval.
• Treatment de-escalation and interruption for some premenopausal and older patients is being studied, but long-term data are incomplete.
• Combinations with precision agents (PI3K/AKT, CDK4/6, PARP in BRCA-associated disease) continue to expand the endocrine-therapy landscape.

8. Unresolved Questions and Speculative Directions

• Optimal duration and sequencing of endocrine therapy, and which patients can safely receive less, remain active questions.
• Whether resistance can be predicted early enough to guide a change in therapy before clinical progression is not yet established. [Marked for verification.]

9. Conclusion

Endocrine therapy is a mature, well-evidenced treatment for hormone-receptor-positive breast cancer and for prostate cancer. Its logic — depriving tumors of hormonal stimulus or blocking the receptor — was among the first successful examples of rational, mechanism-based cancer therapy. Modern progress has come less from new mechanisms than from better agents (aromatase inhibitors, SERDs, potent antiandrogens, abiraterone) and from rationally combining endocrine therapy with targeted agents. Resistance and hormonal toxicity remain the principal limitations, and optimal duration is still an active research question.

Sources and Key Research Centers

• National Cancer Institute — hormone therapy fact sheets and treatment overviews.
• American Society of Clinical Oncology (ASCO) — breast and prostate cancer guidelines.
• European Society for Medical Oncology (ESMO) — guidelines for hormone-receptor-positive breast cancer and prostate cancer.
• Adjuvant tamoxifen: patient-level meta-analysis
  • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). «Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.» The Lancet, 2011; 378(9793): 771–784. DOI: 10.1016/S0140-6736(11)60993-8 [Verify.]
• Aromatase inhibitors vs tamoxifen
  • EBCTCG. «Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.» The Lancet, 2015; 386(10001): 1341–1352. DOI: 10.1016/S0140-6736(15)61074-1 [Verify.]
• Prostate cancer: intensification of ADT — randomized trials of ADT plus abiraterone or androgen-receptor–targeted agents (for example, LATITUDE, STAMPEDE). [Citation details to be verified.]
• ClinicalTrials.gov — ongoing trials of oral SERDs, PROTAC degraders, and endocrine-therapy de-escalation (search terms: oral SERD, ESR1 mutation, endocrine therapy de-escalation).

Note: citation identifiers are provided where available; readers should confirm bibliographic details against the publisher’s record. This article is an editorial scientific overview and is not a medical recommendation.